No evidence inhaled corticosteroids increase osteoporosis risk

group

A study has found that treatment with inhaled corticosteroids does not increase risk of osteoporosis in patients with COPD

Osteoporosis is common in patients with COPD and concerns have been raised about the effect of long term use of inhaled corticosteroids on bone mineral density.

This study, published in Chest, investigated the effects of an inhaled corticosteroid (fluticasone), a long-acting beta-agonist (salmeterol) or the two in combination, on bone mineral density and bone fractures in patients with moderate-to-severe COPD over three years.

Continue reading – Click Here

Share/Bookmark

Leave a Reply

Your email address will not be published. Required fields are marked *